Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07291323
EARLY_PHASE1

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.

Sponsor: Janux Therapeutics

View on ClinicalTrials.gov

Summary

This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.

Official title: A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of JANX011 With Optional Step-Up Dosing in Healthy Adult Volunteers

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-02

Completion Date

2026-12

Last Updated

2025-12-18

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

JANX011

JANX011 is administered subcutaneously, one time.

Locations (1)

CMAX

Adelaide, South Australia, Australia